Work

Disseminated Intravascular Coagulation Following ¹⁷⁷Lu-Dotatate Therapy in a Patient With Metastatic Midgut Neuroendocrine Tumour: A Case Report

Year: 2025

Type: article

Abstract: Peptide receptor radionuclide therapy (PRRT) is an expanding field with ¹⁷⁷Lu-Dotatate emerging as a treatment for midgut neuroendocrine tumours. Haematological side effects are infrequent, and the treatment is generally well tolerated. We present the case of a 70-year-old male patient who developed spontaneous bruising five weeks after his first dose of ¹⁷⁷Lu-Dotatate, with investigations consistent with disseminated intravascular coagulation (DIC). After initially requiring substantial transfusion support, the patient's DIC resolved with the commencement of corticosteroid therapy. This case suggests that DIC may be a rare subacute complication of ¹⁷⁷Lu-Dotatate, and that corticosteroids could be an effective component of management in such instances.

Source: Cureus

DOI: 10.7759/cureus.96945

Authors: Hassan Sharif, Simon McRae

Institutions: Launceston General Hospital, Launceston General Hospital

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4416265146